Search
vorasidenib (Servier)
Indications:
- investigational treatment of gliomas with mutations in isocitrate dehydrogenase-1 & isocitrate dehydrogenase-2 (IDH1, IDH2)
* improves progression-free survival 28 months vs 11 months
Dosage:
- oral administration
Adverse effects:
- 23% vs 14%
- increased serum ALT 10%
Laboratory:
- IDH1 gene mutation
Related
ivosidenib (Tibsovo)
General
small inhibitory antineoplastic agent (ib drug)
References
- Osterwell N
Oral Drug for Brain Tumor Could Change Treatment Landscape
Medscape. June 4, 2023
https://www.medscape.com/viewarticle/992745
- Mellinghoff IK, van den Bent MJ, Blumenthal DT et al
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.
N Engl J Med. 2023. June 4
PMID: 37272516
https://www.nejm.org/doi/10.1056/NEJMoa2304194